[Research Report] The hospital acquired infection treatment market is expected to grow from US$ 15,099.19 million in 2022 to US$ 19,978.39 million by 2030; it is anticipated to record a CAGR of 3.6% from 2022 to 2030.

Market Insights and Analyst View:

Hospital-acquired infections (HAIs), also known as nosocomially acquired infections, may develop in a variety of settings, including hospitals, long-term care institutions, and ambulatory settings, and they can also appear after discharge. HAIs can also involve occupational infections that affect healthcare workers. Key factors driving the hospital acquired infection treatment market growth are high prevalence of HAIs and growing focus on patient safety and quality care. However, the threat of antimicrobial resistance hinders hospital acquired infection treatment market growth.

Growth Drivers and Restraints: 

Central line-associated bloodstream infections, catheter-associated urinary tract infections, and ventilator-associated pneumonia are a few examples of healthcare-associated infections (HAIs). These infections, known as surgical site infections, can also arise at surgical sites. According to the Centers for Disease Control and Prevention (CDC) report “2020 National and State Healthcare-Associated Infections Progress Report" published in 2021, cases of central line-associated bloodstream infections, Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, and ventilator-associated events increased by 24%, 35%, and 15%, respectively, in the US between 2019 and 2020.

Furthermore, According to the January 2022 report from the National Healthcare Safety Network (NHSN), urinary tract infections (UTIs) are the fifth most common type of healthcare-associated infection. UTIs account for more than 9.5% of acute care hospital conditions. Catheter-Associated Urinary Tract Infection (CAUTI) is caused by urinary catheters used to drain urine from the bladder. CAUTI is one of the most frequent infections among hospitalized UTIs patients. According to the Centers for Disease Control and Prevention (CDC), nearly 75% of infections are related to a urinary catheter. During their hospital stays, 15% to 25% of hospitalized patients need to use urinary catheters. Prolonged urinary catheter use is the most major risk factor for getting CAUTI. CAUTI complications entail patient suffering, prolonged hospital stays, increased treatment costs, and even death.

Furthermore, according to the CDC, UTIs are responsible for more than 13,000 deaths each year. Acute uncomplicated cystitis causes around six days of discomfort, resulting in ∼7 million office visits every year at a cost of US$ 1.6 billion. As a result, rising number of HAI cases places a significant financial burden on the healthcare system. The increasing prevalence of CAUTI, combined with the increased demand for drugs for treatment, is propelling the market.

However, antimicrobial resistance poses a significant challenge to HAI treatment, limiting the efficacy of existing antimicrobial agents and necessitating the development of novel treatment strategies and antimicrobial alternatives to combat resistant pathogens effectively.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Hospital Acquired Infection Treatment Market: Strategic Insights

Market Size Value in	US$ 15,099.19 million in 2022
Market Size Value by	US$ 19,978.39 million by 2030
Growth rate	CAGR of 3.6% from 2022 to 2030
Forecast Period	2022-2030
Base Year	2022

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Report Segmentation and Scope:

The global hospital acquired infection treatment market is segmented on the basis of drug class, infection type, and distribution channel. Based on drug class, the hospital acquired infection treatment market is segmented into antibacterial drugs, antiviral drugs, antifungal drugs, and others. Based on infection type, the hospital acquired infection treatment is differentiated into urinary tract infections, ventilator-associated pneumonia, surgical site infections, bloodstream infections, and other hospital infections. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, e-commerce, and others. The hospital acquired infection treatment market, based on geography, is segmented into North America (the US, Canada, and Mexico), Europe (Germany, France, Italy, the UK, Russia, and the Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:

The hospital acquired infection treatment market, by drug class, is segmented into antibacterial drugs, antiviral drugs, antifungal drugs, and others. The antibacterial drugs segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022–2030.

The hospital acquired infection treatment market, by infection type, is segmented into urinary tract infections, ventilator-associated pneumonia, surgical site infections, bloodstream infections, and other hospital infections. The urinary tract infections segment held the largest market share in 2022. However, the ventilator-associated pneumonia segment is anticipated to register the highest CAGR from 2022 to 2030.

The hospital acquired infection treatment market, by distribution channel, is segmented into hospital pharmacies, retail pharmacies, e-commerce, and others. In 2022, the hospital pharmacies segment held the largest market share, and the same segment is anticipated to register the highest CAGR during 2022–2030.

Regional Analysis:

Based on geography, the global hospital acquired infection treatment market is segmented into five key regions—North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

In 2022, North America held the largest share of the global hospital acquired infection treatment market size. The US has a high prevalence of HAI, which propels the hospital acquired infection treatment market growth. As per the CDC, on any given day, about 1 in 31 hospital patients has at least one HAI. Similarly, according to the Office of Disease Prevention and Health Promotion, HAIs and other infections can lead to sepsis, and it causes an ∼1.7 million illness cases and 270,000 deaths per year in the US. Thus, the high prevalence of HAI among people in the US fuels the hospital acquired infection treatment market growth.  

Industry Developments and Future Opportunities:

Various initiatives taken by key players operating in the global hospital acquired infection treatment market are listed below:

1. In May 2023, Innoviva Specialty Therapeutics announced that the US Food and Drug Administration (FDA) had approved XACDURO (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use in patients aged 18 years and above for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter). Innoviva Specialty Therapeutics stated that it is focused on delivering innovative therapies in critical care and infectious diseases.
2. In May 2023, Researchers of the Indian Institute of Science Education and Research (IISER), Pune and Central Drug Research Institute (CSIR-CDRI), Lucknow announced that they had discovered a potential new antibiotic against Acinetobacter baumannii, which frequently causes HAIs.
3. In September 2020, Shionogi & Co Ltd announced that the FDA had approved a supplemental New Drug Application (sNDA) for FETROJA (cefiderocol) for the treatment of patients aged 18 years and above with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible Gram-negative microorganisms such as Enterobacter cloacae complex, Klebsiella pneumoniae, Acinetobacter baumannii complex, Escherichia coli, Pseudomonas aeruginosa, and Serratia marcescens.
4. In June 2020, Merck announced that the US Food and Drug Administration (FDA) had approved a supplemental New Drug Application (sNDA) for RECARBRIO (imipenem, cilastatin, and relebactam) for the treatment of patients aged 18 years and above suffering from hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible Gram-negative microorganisms such as Acinetobacter calcoaceticus-baumannii complex, Klebsiella oxytoca, Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella aerogenes, Pseudomonas aeruginosa, and Serratia marcescens.

Hospital Acquired Infection Treatment Market Report Scope

Competitive Landscape and Key Companies:

Merck & Co Inc, Pfizer Inc, AbbVie Inc, Paratek Pharmaceuticals Inc, Eugia US LLC, Abbott Laboratories, Cumberland Pharmaceuticals Inc, Innoviva Specialty Therapeutics Inc, Cipla Ltd, and Eli Lilly and Company are among the prominent players operating in the hospital acquired infection treatment market. These companies focus on new technologies, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios.